Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Without Methotrexate (MTX) Therapy

Next Previous
Search
Trial Profile

A Phase III Study of TS-152 in Patients with Active Rheumatoid Arthritis (RA) Without Methotrexate (MTX) Therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozoralizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
  • Acronyms NATSUZORA
  • Sponsors Taisho Pharmaceutical

    • Most Recent Events

    • 13 Apr 2023 Results of post hoc analysis assessing the pharmacokinetics of the drug and its correlation with clinical efficacy (52-week results) in patients with rheumatoid arthritis from the OHZORA and NATSUZORA trials, published in the Arthritis Research and Therapy.
    • 01 Nov 2022 Status changed from recruiting to completed.
    • 26 Sep 2022 According to a Taisho Pharmaceutical media release, the company received approval to manufacture and market Nanozora 30mg Syringes for S.C. Injection from the Ministry of Health, Labour and Welfare for the indication of rheumatoid arthritis (RA), based on data from OHZORA and NATSUZORA study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top